Daan T Geraets1, Antoon W Grünberg2, Jannie J van der Helm3, Maarten F Schim van der Loeff4, Koen D Quint5, Leslie O A Sabajo6, Henry J C de Vries7. 1. DDL Diagnostic Laboratory, Rijswijk, The Netherlands. 2. Department of Public Health, Ministry of Health, Paramaribo, Suriname. 3. STI Outpatient Clinic, Public Health Service Amsterdam, Amsterdam, The Netherlands Department of Research, Public Health Service Amsterdam, Amsterdam, The Netherlands. 4. Department of Research, Public Health Service Amsterdam, Amsterdam, The Netherlands Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. 5. DDL Diagnostic Laboratory, Rijswijk, The Netherlands Department of Dermatology LUMC, University of Leiden, Leiden, The Netherlands. 6. Dermatological Service, Ministry of Health, Paramaribo, Suriname. 7. STI Outpatient Clinic, Public Health Service Amsterdam, Amsterdam, The Netherlands Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands Centre for Infectious Disease Control, National Institute of Public Health and the Environment, Bilthoven, The Netherlands.
Abstract
OBJECTIVE: Cervical cancer is caused by carcinogenic human papillomavirus (HPV) infections. Prior to the introduction of HPV vaccination in Suriname, we performed a cross-sectional study to estimate the prevalence of and determinants for genital carcinogenic HPV infections. METHODS: Women were recruited at a family planning (FP) clinic and a sexually transmitted infections (STI) clinic. Vaginal swabs were used for HPV genotyping by the SPF10 PCR-DEIA-LiPA25 system. Logistic regression was used to identify determinants for carcinogenic HPV infection. RESULTS: The prevalence of any HPV was 54.2% and of carcinogenic HPV was 27.9% among 813 women attending the FP clinic. Among the 188 women attending the STI clinic, the prevalence of any HPV (76.1%) and of carcinogenic HPV (40.4%) was significantly higher. HPV52 was the most prevalent genotype in both clinics. The prevalence of HPV16 and/or 18 was 6.4% in the FP clinic and 12.2% in the STI clinic. The following determinants were independently associated with carcinogenic HPV infection among women visiting the FP clinic: ≥2 recent partners (OR 1.53; 95% CI 1.13 to 2.06), Chlamydia trachomatis co-infection (OR 1.89; 95% CI 1.32 to 2.70), disassortative ethnic sexual mixing (OR 1.50; 95% CI 1.13 to 1.99) and ethnic group (OR 1.90; 95% CI 1.27 to 2.85 for Creole and OR 1.67; 95% CI 1.06 to 2.62 for mixed ethnicity, both compared with Hindustani). No independent determinants were found among women visiting the STI clinic. CONCLUSIONS: Carcinogenic HPV is highly prevalent among women in Suriname, and not equally distributed among ethnic groups. These data provide a baseline to assess possible shifts in the prevalence of HPV genotypes following vaccination. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
OBJECTIVE: Cervical cancer is caused by carcinogenic human papillomavirus (HPV) infections. Prior to the introduction of HPV vaccination in Suriname, we performed a cross-sectional study to estimate the prevalence of and determinants for genital carcinogenic HPV infections. METHODS:Women were recruited at a family planning (FP) clinic and a sexually transmitted infections (STI) clinic. Vaginal swabs were used for HPV genotyping by the SPF10 PCR-DEIA-LiPA25 system. Logistic regression was used to identify determinants for carcinogenic HPV infection. RESULTS: The prevalence of any HPV was 54.2% and of carcinogenic HPV was 27.9% among 813 women attending the FP clinic. Among the 188 women attending the STI clinic, the prevalence of any HPV (76.1%) and of carcinogenic HPV (40.4%) was significantly higher. HPV52 was the most prevalent genotype in both clinics. The prevalence of HPV16 and/or 18 was 6.4% in the FP clinic and 12.2% in the STI clinic. The following determinants were independently associated with carcinogenic HPV infection among women visiting the FP clinic: ≥2 recent partners (OR 1.53; 95% CI 1.13 to 2.06), Chlamydia trachomatis co-infection (OR 1.89; 95% CI 1.32 to 2.70), disassortative ethnic sexual mixing (OR 1.50; 95% CI 1.13 to 1.99) and ethnic group (OR 1.90; 95% CI 1.27 to 2.85 for Creole and OR 1.67; 95% CI 1.06 to 2.62 for mixed ethnicity, both compared with Hindustani). No independent determinants were found among women visiting the STI clinic. CONCLUSIONS:Carcinogenic HPV is highly prevalent among women in Suriname, and not equally distributed among ethnic groups. These data provide a baseline to assess possible shifts in the prevalence of HPV genotypes following vaccination. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Filipa Godoy-Vitorino; Josefina Romaguera; Chunyu Zhao; Daniela Vargas-Robles; Gilmary Ortiz-Morales; Frances Vázquez-Sánchez; Maria Sanchez-Vázquez; Manuel de la Garza-Casillas; Magaly Martinez-Ferrer; James Robert White; Kyle Bittinger; Maria Gloria Dominguez-Bello; Martin J Blaser Journal: Front Microbiol Date: 2018-10-23 Impact factor: 5.640
Authors: Vera de Geus; Patricia C Ewing-Graham; Willem de Koning; Maurits N C de Koning; Thierry P P van den Bosch; Alex L Nigg; Casper H J van Eijck; Marta Jozwiak; Heleen J van Beekhuizen; Dana A M Mustafa Journal: Front Oncol Date: 2022-01-11 Impact factor: 6.244
Authors: Desiree J Hooi; Birgit I Lissenberg-Witte; Maurits N C de Koning; Herbert M Pinedo; Gemma G Kenter; Chris Jlm Meijer; Wim G Quint Journal: Sex Transm Infect Date: 2017-10-11 Impact factor: 3.519
Authors: Daniela Vargas-Robles; Magda Magris; Natalia Morales; Maurits N C de Koning; Iveth Rodríguez; Tahidid Nieves; Filipa Godoy-Vitorino; Gloria I Sánchez; Luis David Alcaraz; Larry J Forney; María-Eglée Pérez; Luis García-Briceño; Leen-Jan van Doorn; María Gloria Domínguez-Bello Journal: mSphere Date: 2018-05-02 Impact factor: 4.389